The CD160, BTLA, LIGHT/HVEM pathway: A bidirectional switch regulating T-cell activation

Immunological Reviews

Volumn 229, Issue 1, 2009, Pages 244-258

  Cai, Guifang ^a   Freeman, Gordon J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BTLA; CD160; Coinhibition; Costimulation; HVEM; LIGHT

Indexed keywords

ABATACEPT; HERPESVIRUS ENTRY MEDIATOR; HERPESVIRUS ENTRY MEDIATOR LIGAND; HERPESVIRUS ENTRY MEDIATOR LIGAND BTLA; HERPESVIRUS ENTRY MEDIATOR LIGAND CD160; HERPESVIRUS ENTRY MEDIATOR LIGAND LIGHT; LYMPHOTOXIN; LYMPHOTOXIN ALPHA BETA; LYMPHOTOXIN BETA RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BY55; MONOCLONAL ANTIBODY CD160; MONOCLONAL ANTIBODY CL1 R2; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CELL SURFACE; CELLULAR DISTRIBUTION; CYTOLYSIS; CYTOTOXICITY; DENDRITIC CELL; GRAFT VERSUS HOST REACTION; HOMEOSTASIS; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFECTION; LIGAND BINDING; NATURAL KILLER CELL; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; T LYMPHOCYTE ACTIVATION; TISSUE DISTRIBUTION; TUMOR IMMUNOLOGY; VACCINATION;

ANIMALS; ANTIGENS, CD; AUTOIMMUNITY; HUMANS; INFECTION; LYMPHOCYTE ACTIVATION; LYMPHOTOXIN-ALPHA; NEOPLASMS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

EID: 65349084376     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2009.00783.x     Document Type: Review

References (145)

1. Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci USA 1999 96 : 185 190.
2. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993 90 : 6586 6590.
3. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005 23 : 515 548.
4. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 2006 203 : 2223 2227.
5. Sedy JR, et al. B and T lymphocyte attenuator regulates T-cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005 6 : 90 98.
6. Cai G, Anumanthan A, Brown JA, Greenfield EA, Zhu B, Freeman GJ. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol 2008 9 : 176 185.
7. Mauri DN, et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998 8 : 21 30.
8. Watanabe N, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003 4 : 670 679.
9. Ware CF, VanArsdale TL, Crowe PD, Browning JL. The ligands and receptors of the lymphotoxin system. Curr Top Microbiol Immunol 1995 198 : 175 218.
10. Granger SW, Ware CF. Turning on LIGHT. J Clin Invest 2001 108 : 1741 1742.
11. Wang Y, et al. The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest 2005 115 : 711 717.
12. Montgomery RI, Warner MS, Lum BJ, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996 87 : 427 436.
13. Ware CF. Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways. Immunol Rev 2008 223 : 186 201.
14. Maiza H, Leca G, Mansur IG, Schiavon V, Boumsell L, Bensussan A. A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity. J Exp Med 1993 178 : 1121 1126.
15. Anumanthan A, et al. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J Immunol 1998 161 : 2780 2790.
16. Giustiniani J, Bensussan A, Marie-Cardine A. Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation. J Immunol 2009 182 : 63 71.
17. Agrawal S, et al. Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells. J Immunol 1999 162 : 1223 1226.
18. Blackburn SD, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009 10 : 29 37.
19. Maeda M, et al. Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation. J Immunol 2005 175 : 4426 4432.
20. Tsujimura K, et al. Characterization of murine CD160+ CD8+ T lymphocytes. Immunol Lett 2006 106 : 48 56.
21. Buttner P, Mosig S, Lechtermann A, Funke H, Mooren FC. Exercise affects the gene expression profiles of human white blood cells. J Appl Physiol 2007 102 : 26 36.
22. Proll J, Bensussan A, Goffin F, Foidart JM, Berrebi A, Le Bouteiller P. Tubal versus uterine placentation: similar HLA-G expressing extravillous cytotrophoblast invasion but different maternal leukocyte recruitment. Tissue Antigens 2000 56 : 479 491.
23. Fons P, et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood 2006 108 : 2608 2615.
24. Rabot M, Bensussan A, Le Bouteiller P. Engagement of the CD160 activating NK cell receptor leads to its association with CD2 in circulating human NK cells. Transpl Immunol 2006 17 : 36 38.
25. Giustiniani J, Marie-Cardine A, Bensussan A. A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity. J Immunol 2007 178 : 1293 1300.
26. Bensussan A, et al. BY55 monoclonal antibody delineates within human cord blood and bone marrow lymphocytes distinct cell subsets mediating cytotoxic activity. Proc Natl Acad Sci USA 1994 91 : 9136 9140.
27. Merino J, Ramirez N, Moreno C, Toledo E, Fernandez M, Sanchez-Ibarrola A. BY55/CD160 cannot be considered a cytotoxic marker in cytomegalovirus-specific human CD8(+) T cells. Clin Exp Immunol 2007 149 : 87 96.
28. Gonzalez LC, et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci USA 2005 102 : 1116 1121.
29. Hsu H, Solovyev I, Colombero A, Elliott R, Kelley M, Boyle WJ. ATAR, a novel tumor necrosis factor receptor family member, signals through TRAF2 and TRAF5. J Biol Chem 1997 272 : 13471 13474.
30. Morel Y, Truneh A, Sweet RW, Olive D, Costello RT. The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J Immunol 2001 167 : 2479 2486.
31. Harrop JA, et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem 1998 273 : 27548 27556.
32. Tamada K, et al. LIGHT, a TNF-like molecule, costimulates T-cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 2000 164 : 4105 4110.
33. Duhen T, Pasero C, Mallet F, Barbarat B, Olive D, Costello RT. LIGHT costimulates CD40 triggering and induces immunoglobulin secretion: a novel key partner in T cell-dependent B cell terminal differentiation. Eur J Immunol 2004 34 : 3534 3541.
34. Harrop JA, et al. Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T-cell proliferation, expression of activation markers, and production of cytokines. J Immunol 1998 161 : 1786 1794.
35. Banner DW, et al. Crystal structure of the soluble human 55 kD TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993 73 : 431 445.
36. Eck MJ, Ultsch M, Rinderknecht E, de Vos AM, Sprang SR. The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution. J Biol Chem 1992 267 : 2119 2122.
37. Eck MJ, Sprang SR. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem 1989 264 : 17595 17605.
38. Eck MJ, Beutler B, Kuo G, Merryweather JP, Sprang SR. Crystallization of trimeric recombinant human tumor necrosis factor (cachectin). J Biol Chem 1988 263 : 12816 12819.
39. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999 274 : 13733 13736.
40. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002 27 : 19 26.
41. Zhai Y, et al. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest 1998 102 : 1142 1151.
42. Morel Y, et al. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J Immunol 2000 165 : 4397 4404.
43. Shi G, Luo H, Wan X, Salcedo TW, Zhang J, Wu J. Mouse T cells receive costimulatory signals from LIGHT, a TNF family member. Blood 2002 100 : 3279 3286.
44. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005 23 : 23 68.
45. Wang J, et al. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J Clin Invest 2001 108 : 1771 1780.
46. Shaikh RB, et al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J Immunol 2001 167 : 6330 6337.
47. Wang J, et al. The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function. Eur J Immunol 2002 32 : 1969 1979.
48. Wang YG, Kim KD, Wang J, Yu P, Fu YX. Stimulating lymphotoxin beta receptor on the dendritic cells is critical for their homeostasis and expansion. J Immunol 2005 175 : 6997 7002.
49. Ngo VN, Cornall RJ, Cyster JG. Splenic T zone development is B cell dependent. J Exp Med 2001 194 : 1649 1660.
50. De Trez C, Ware CF. The TNF receptor and Ig superfamily members form an integrated signaling circuit controlling dendritic cell homeostasis. Cytokine Growth Factor Rev 2008 19 : 277 284.
51. Liu J, et al. LIGHT-deficiency impairs CD8+ T cell expansion, but not effector function. Int Immunol 2003 15 : 861 870.
52. Wang J, et al. The critical role of LIGHT, a TNF family member, in T cell development. J Immunol 2001 167 : 5099 5105.
53. Wang J, Fu YX. LIGHT (a cellular ligand for herpes virus entry mediator and lymphotoxin receptor)-mediated thymocyte deletion is dependent on the interaction between TCR and MHC/self-peptide. J Immunol 2003 170 : 3986 3993.
54. Scheu S, Alferink J, Potzel T, Barchet W, Kalinke U, Pfeffer K. Targeted disruption of LIGHT causes defects in costimulatory T-cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J Exp Med 2002 195 : 1613 1624.
55. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994 76 : 959 962.
56. Hymowitz SG, et al. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000 39 : 633 640.
57. Mongkolsapaya J, et al. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 1999 6 : 1048 1053.
58. Ansel KM, et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000 406 : 309 314.
59. Shacks SJ, Chiller J, Granger GA. Studies on in vitro models of cellular immunity: the role of T and B cells in the secretion of lymphotoxin. Cell Immunol 1973 7 : 313 321.
60. Eardley DD, Shen FW, Gershon RK, Ruddle NH. Lymphotoxin production by subsets of T cells. J Immunol 1980 124 : 1199 1202.
61. Ware CF, Crowe PD, Grayson MH, Androlewicz MJ, Browning JL. Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J Immunol 1992 149 : 3881 3888.
62. Browning JL, et al. Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes. J Immunol 1997 159 : 3288 3298.
63. Browning JL, French LE. Visualization of lymphotoxin-beta and lymphotoxin-beta receptor expression in mouse embryos. J Immunol 2002 168 : 5079 5087.
64. De Togni P, et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 1994 264 : 703 707.
65. Mebius RE. Organogenesis of lymphoid tissues. Nat Rev Immunol 2003 3 : 292 303.
66. Muller G, Lipp M. Concerted action of the chemokine and lymphotoxin system in secondary lymphoid-organ development. Curr Opin Immunol 2003 15 : 217 224.
67. Fu YX, Chaplin DD. Development and maturation of secondary lymphoid tissues. Annu Rev Immunol 1999 17 : 399 433.
68. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001 104 : 487 501.
69. Loyet KM, Ouyang W, Eaton DL, Stults JT. Proteomic profiling of surface proteins on Th1 and Th2 cells. J Proteome Res 2005 4 : 400 409.
70. Hurchla MA, Sedy JR, Gavrieli M, Drake CG, Murphy TL, Murphy KM. B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+ T cells. J Immunol 2005 174 : 3377 3385.
71. Han P, Goularte OD, Rufner K, Wilkinson B, Kaye J. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J Immunol 2004 172 : 5931 5939.
72. Otsuki N, Kamimura Y, Hashiguchi M, Azuma M. Expression and function of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells. Biochem Biophys Res Commun 2006 344 : 1121 1127.
73. Compaan DM, Gonzalez LC, Tom I, Loyet KM, Eaton D, Hymowitz SG. Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex. J Biol Chem 2005 280 : 39553 39561.
74. Le Bouteiller P, et al. Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. Proc Natl Acad Sci USA 2002 99 : 16963 16968.
75. Barakonyi A, et al. Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset. J Immunol 2004 173 : 5349 5354.
76. Rabot M, et al. CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment. Int Immunol 2007 19 : 401 409.
77. Lepenies B, et al. Ligation of B and T lymphocyte attenuator prevents the genesis of experimental cerebral malaria. J Immunol 2007 179 : 4093 5100.
78. Le Bouteiller P, et al. Soluble HLA-G and control of angiogenesis. J Reprod Immunol 2007 76 : 17 22.
79. Nikolova M, Marie-Cardine A, Boumsell L, Bensussan A. BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression. Int Immunol 2002 14 : 445 451.
80. Rey J, et al. The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function. Eur J Immunol 2006 36 : 2359 2366.
81. Ha SJ, West EE, Araki K, Smith KA, Ahmed R. Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol Rev. 2008 223 : 317 333.
82. Wherry EJ, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007 27 : 670 684.
83. Bensussan A, Rabian C, Schiavon V, Bengoufa D, Leca G, Boumsell L. Significant enlargement of a specific subset of CD3+CD8+ peripheral blood leukocytes mediating cytotoxic T-lymphocyte activity during human immunodeficiency virus infection. Proc Natl Acad Sci USA 1993 90 : 9427 9430.
84. Peretz Y, et al. Elite controllers are enriched with HIV-specific cells expressing CD160 but lacking PD-1. Abstract 356. 16th Conference on retroviruses and opportunistic infections. Montreal, Canada, 2009.
85. Murphy KM, Nelson CA, Sedy JR. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev Immunol 2006 6 : 671 681.
86. Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 1994 6 : 407 413.
87. Sarrias MR, et al. The three HveA receptor ligands, gD, LT-alpha and LIGHT bind to distinct sites on HveA. Mol Immunol 2000 37 : 665 673.
88. Cheung TC, et al. Evolutionarily divergent herpesviruses modulate T-cell activation by targeting the herpesvirus entry mediator cosignaling pathway. Proc Natl Acad Sci USA 2005 102 : 13218 13223.
89. Marsters SA, Ayres TM, Skubatch M, Gray CL, Rothe M, Ashkenazi A. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem 1997 272 : 14029 14032.
90. Kwon BS, et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem 1997 272 : 14272 14276.
91. Kabashima K, Banks TA, Ansel KM, Lu TT, Ware CF, Cyster JG. Intrinsic lymphotoxin-beta receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity 2005 22 : 439 450.
92. Xu G, et al. LIGHT is critical for IL-12 production by dendritic cells, optimal CD4+ Th1 cell response, and resistance to Leishmania major. J Immunol 2007 179 : 6901 6909.
93. Rooney IA, et al. The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J Biol Chem 2000 275 : 14307 14315.
94. Gavrieli M, Watanabe N, Loftin SK, Murphy TL, Murphy KM. Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem Biophys Res Commun 2003 312 : 1236 1243.
95. Moran M, Miceli MC. Engagement of GPI-linked CD48 contributes to TCR signals and cytoskeletal reorganization: a role for lipid rafts in T-cell activation. Immunity 1998 9 : 787 796.
96. Stefanova I, Horejsi V, Ansotegui IJ, Knapp W, Stockinger H. GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. Science 1991 254 : 1016 1019.
97. Dianzani U, et al. Co-stimulatory signal delivered by CD73 molecule to human CD45RAhiCD45ROlo (naive) CD8+ T lymphocytes. J Immunol 1993 151 : 3961 3970.
98. Keller P, Toomre D, Diaz E, White J, Simons K. Multicolour imaging of post-Golgi sorting and trafficking in live cells. Nat Cell Biol 2001 3 : 140 149.
99. Nicholson TB, Stanners CP. Identification of a novel functional specificity signal within the GPI anchor signal sequence of carcinoembryonic antigen. J Cell Biol 2007 177 : 211 218.
100. Brown DA, Rose JK. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell 1992 68 : 533 544.
101. Mayor S, Riezman H. Sorting GPI-anchored proteins. Nat Rev Mol Cell Biol 2004 5 : 110 120.
102. Maeda Y, et al. Fatty acid remodeling of GPI-anchored proteins is required for their raft association. Mol Biol Cell 2007 18 : 1497 1506.
103. Casey PJ. Protein lipidation in cell signaling. Science 1995 268 : 221 225.
104. Skibbens JE, Roth MG, Matlin KS. Differential extractability of influenza virus hemagglutinin during intracellular transport in polarized epithelial cells and nonpolar fibroblasts. J Cell Biol 1989 108 : 821 832.
105. Danielsen EM. Involvement of detergent-insoluble complexes in the intracellular transport of intestinal brush border enzymes. Biochemistry 1995 34 : 1596 1605.
106. Suzuki KG, Fujiwara TK, Sanematsu F, Iino R, Edidin M, Kusumi A. GPI-anchored receptor clusters transiently recruit Lyn and G alpha for temporary cluster immobilization and Lyn activation: single-molecule tracking study 1. J Cell Biol 2007 177 : 717 730.
107. Montixi C, et al. Engagement of T cell receptor triggers its recruitment to low-density detergent-insoluble membrane domains. EMBO J 1998 17 : 5334 5348.
108. Janes PW, Ley SC, Magee AI, Kabouridis PS. The role of lipid rafts in T cell antigen receptor (TCR) signalling. Semin Immunol 2000 12 : 23 34.
109. Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 1999 283 : 680 682.
110. Bromley SK, et al. The immunological synapse and CD28-CD80 interactions. Nat Immunol 2001 2 : 1159 1166.
111. Jones DR, Varela-Nieto I. The role of glycosyl-phosphatidylinositol in signal transduction. Int J Biochem Cell Biol 1998 30 : 313 326.
112. Robinson PJ. Signal transduction via GPI-anchored membrane proteins. Adv Exp Med Biol 1997 419 : 365 370.
113. Tamada K, et al. Cutting edge: selective impairment of CD8+ T cell function in mice lacking the TNF superfamily member LIGHT. J Immunol 2002 168 : 4832 4835.
114. Schneider K, Potter KG, Ware CF. Lymphotoxin and LIGHT signaling pathways and target genes. Immunol Rev 2004 202 : 49 66.
115. Gavrieli M, Murphy KM. Association of Grb-2 and PI3K p85 with phosphotyrosile peptides derived from BTLA. Biochem Biophys Res Commun 2006 345 : 1440 1445.
116. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001 1 : 220 228.
117. Vendel AC, et al. B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK. J Immunol 2009 182 : 1509 1517.
118. Tamada K, et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med 2000 6 : 283 289.
119. De Trez C, et al. The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells. J Immunol 2008 180 : 238 248.
120. Oya Y, et al. Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum 2008 58 : 2498 2510.
121. Abecassis S, et al. Identification of a novel CD160+ CD4+ T-lymphocyte subset in the skin: a possible role for CD160 in skin inflammation. J Invest Dermatol 2007 127 : 1161 1166.
122. Deppong C, et al. Cutting edge: B and T lymphocyte attenuator and programmed death receptor-1 inhibitory receptors are required for termination of acute allergic airway inflammation. J Immunol 2006 176 : 3909 3913.
123. Shen N, Tsao BP. Current advances in the human lupus genetics. Curr Rheumatol Rep 2004 6 : 391 398.
124. Reich D, et al. A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility. Nat Genet 2005 37 : 1113 1118.
125. Lyons PA, et al. Mapping by genetic interaction: high-resolution congenic mapping of the type 1 diabetes loci Idd10 and Idd18 in the NOD mouse. Diabetes 2001 50 : 2633 2637.
126. Hurchla MA, Sedy JR, Murphy KM. Unexpected role of B and T lymphocyte attenuator in sustaining cell survival during chronic allostimulation. J Immunol 2007 178 : 6073 6082.
127. Krieg C, Boyman O, Fu YX, Kaye J. B and T lymphocyte attenuator regulates CD8+ T cell-intrinsic homeostasis and memory cell generation. Nat Immunol 2007 8 : 162 171.
128. Ye Q, et al. Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival. J Exp Med 2002 195 : 795 800.
129. Fan K, et al. Blockade of LIGHT/HVEM and B7/CD28 signaling facilitates long-term islet graft survival with development of allospecific tolerance. Transplantation 2007 84 : 746 754.
130. Truong W, et al. Negative and positive co-signaling with anti-BTLA (PJ196) and CTLA4Ig prolongs islet allograft survival. Transplantation 2007 84 : 1368 1372.
131. Truong W, et al. Combined coinhibitory and costimulatory modulation with anti-BTLA and CTLA4Ig facilitates tolerance in murine islet allografts. Am J Transplant 2007 7 : 2663 2674.
132. Tao R, Wang L, Murphy KM, Fraser CC, Hancock WW. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J Immunol 2008 180 : 6649 6655.
133. Rux AH, et al. Functional region IV of glycoprotein D from herpes simplex virus modulates glycoprotein binding to the herpesvirus entry mediator. J Virol 1998 72 : 7091 7098.
134. Willis SH, et al. Examination of the kinetics of herpes simplex virus glycoprotein D binding to the herpesvirus entry mediator, using surface plasmon resonance. J Virol 1998 72 : 5937 5947.
135. Whitbeck JC, et al. Localization of the gD-binding region of the human herpes simplex virus receptor, HveA. J Virol 2001 75 : 171 180.
136. Lasaro MO, et al. Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat Med 2008 14 : 205 212.
137. Lasaro MO, Ertl HC. Potentiating vaccine immunogenicity by manipulating the HVEM/BTLA pathway and other co-stimulatory and co-inhibitory signals of the immune system. Hum Vaccin 2008 5 : 6 14.
138. Lasaro MO, Diniz MO, Reyes-Sandoval A, Ertl HC, Ferreira LC. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1. Microbes Infect 2005 7 : 1541 1550.
139. Xu G, et al. Lymphotoxin alpha beta 2 (membrane lymphotoxin) is critically important for resistance to Leishmania major infection in mice. J Immunol 2007 179 : 5358 5366.
140. Yu P, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004 5 : 141 149.
141. Fan Z, et al. NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood 2006 107 : 1342 1351.
142. Costello RT, et al. Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity. Leukemia 2003 17 : 2500 2507.
143. Gommerman JL, Browning JL. Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol 2003 3 : 642 655.
144. Pakala SV, Ilic A, Chen L, Sarvetnick N. TNF-alpha receptor 1 (p55) on islets is necessary for the expression of LIGHT on diabetogenic T cells. Clin Immunol 2001 100 : 198 207.
145. Nelson CA, et al. Structural determinants of herpesvirus entry mediator recognition by murine B and T lymphocyte attenuator. J Immunol 2008 180 : 940 947.